Eiger BioPharmaceuticals: Funding, Investors & Team (Sep 2026)
Eiger BioPharmaceuticals is a secretly held biotechnology organization that fosters a clever antiviral treatment for Hepatitis Delta, a perilous, Orphan Disease with high neglected clinical need and no supported treatment. The organization is driven by a supervisory group experienced in the turn of events and commercialization of uncommon sickness therapeutics. Its technique is predicated upon time and cost-productive medication improvement, determined to convey protected and successful treatments to patients.
Eiger BioPharmaceuticals has raised $75.0M across 1 funding round on record, the most recent a Post-IPO Debt of $75.0M announced in Jun 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eiger BioPharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2022.
Eiger BioPharmaceuticals Funding Rounds
Eiger BioPharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Eiger BioPharmaceuticals Funding Compared to Other Biotechnology Startups
Eiger BioPharmaceuticals' latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eiger BioPharmaceuticals in Biotechnology and San Carlos
Companies Similar to Eiger BioPharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Eiger BioPharmaceuticals Funding FAQs
What does Eiger BioPharmaceuticals do?
Eiger BioPharmaceuticals is a secretly held biotechnology organization that fosters a clever antiviral treatment for Hepatitis Delta, a perilous, Orphan Disease with high neglected clinical need and no supported treatment. The organization is driven by a supervisory group experienced in the turn of events and commercialization of uncommon sickness therapeutics. Its technique is predicated upon time and cost-productive medication improvement, determined to convey protected and successful treatments to patients.
How much funding has Eiger BioPharmaceuticals raised?
Eiger BioPharmaceuticals has raised $75.0M across 1 round on record. The most recent is a Post-IPO Debt of $75.0M announced in Jun 2022.
When did Eiger BioPharmaceuticals last raise funding?
Eiger BioPharmaceuticals' most recent funding round on record is a Post-IPO Debt of $75.0M, announced in Jun 2022.
Who founded Eiger BioPharmaceuticals?
FundedIQ lists Jeffrey Glenn (Founder) at Eiger BioPharmaceuticals.
Where is Eiger BioPharmaceuticals headquartered?
Eiger BioPharmaceuticals is based in San Carlos, California, United States.
How many employees does Eiger BioPharmaceuticals have?
Eiger BioPharmaceuticals is in the 11-50 employee band.
How does Eiger BioPharmaceuticals' funding compare to other Biotechnology startups?
Eiger BioPharmaceuticals' latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Eiger BioPharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eiger BioPharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.